Oncolytic Measles Virus Encoding Thyroidal Sodium Iodide Symporter
Fallopian Tube Transitional Cell Carcinoma
Floatz Rating
B59/100
Confidence
Indicative
Sponsor
Mayo Clinic
Modality
gene_therapy
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
44Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT02364713CT.gov MV-NIS or Investigator's Choice Chemotherapy in Treating Patients With Ovarian, Fallopian, or Peritoneal Cancer | — | Terminated | — | — | — |
NCT02068794CT.gov MV-NIS Infected Mesenchymal Stem Cells in Treating Recurrent Ovarian, Primary Peritoneal or Fallopian Tube Cancer | — | Active Not Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Fallopian Tube Transitional Cell Carcinoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Oncolytic Measles Virus Encoding Thyroidal Sodium Iodide Symporter (this asset) | Mayo Clinic | P2 | B · 59 |
| Carboplatin | National Cancer Institute (NCI) | P3 | BBB |
| Adriamycin | National Cancer Institute (NCI) | P3 | BB |
| Cediranib | National Cancer Institute (NCI) | P3 | BB |
| Olaparib | National Cancer Institute (NCI) | P3 | BB |
| Cis-Diamminedichloroplatinum Ii | National Cancer Institute (NCI) | P3 | BB |
| Nogitecan | National Cancer Institute (NCI) | P2/3 | BB |
| Docetaxel | National Cancer Institute (NCI) | P3 | B |
| Elesclomol | GOG Foundation | P2 | B |
+7 more in the Fallopian Tube Transitional Cell Carcinoma cohort
Other indications for Oncolytic Measles Virus Encoding Thyroidal Sodium Iodide Symporter
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Primary Peritoneal Carcinoma | — | P2 | B · 63 |
| Fallopian Tube Serous Adenocarcinoma | — | P2 | B · 59 |
| Fallopian Tube Mucinous Adenocarcinoma | — | P2 | B · 59 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Citation
Floatz Terminal. Oncolytic Measles Virus Encoding Thyroidal Sodium Iodide Symporter in Fallopian Tube Transitional Cell Carcinoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 13, 2026. https://terminal.floatz.ai/assets/oncolytic-measles-virus-encoding-thyroidal-sodium-iodide-symporter-fallopian-tube-transitional-cell-carcinoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →